Stratec Se

Stratec Se ROCE

The Return on Capital Employed (ROCE) of Stratec Se (SBS.DE) as of Oct 12, 2026 is 3.62 %. In the previous year, Return on Capital Employed (ROCE) was 11.62 % — a change of -68.84% (lower).

ROCE

3.62 %

YoY

-68.84%

Last updated:

In 2025, Stratec Se's return on capital employed (ROCE) was 3.62 %, a -68.84% increase from the 11.62 % ROCE in the previous year.

The Stratec Se ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
10.11 EUR
Jan 1, 2019
11.45 EUR
Jan 1, 2020
19.42 EUR
Jan 1, 2021
24.12 EUR
Jan 1, 2022
18.65 EUR
Jan 1, 2023
12.05 EUR
Jan 1, 2024
11.62 EUR
Jan 1, 2025
3.62 EUR
The Stratec Se ROCE history
YEARROCEYoY
3.62 %-68.84%
11.62 %-3.60%
12.05 %-35.37%
18.65 %-22.68%
24.12 %+24.19%
19.42 %+69.64%
11.45 %+13.29%
10.11 %-47.72%
19.33 %+14.79%
16.84 %-18.36%
20.63 %-3.90%
21.47 %—
Access this data via the Eulerpool API

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Stratec Se's Return on Capital Employed (ROCE)

Stratec Se's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Stratec Se's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Stratec Se's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Stratec Se’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Stratec Se stock

Return on Capital Employed (ROCE) of Stratec Se is 3.62 % in 2025.

Return on Capital Employed (ROCE) of Stratec Se changed from 11.62 % to 3.62 %, representing a -68.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Stratec Se since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Stratec Se with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — Stratec Se

All Key Metrics — Stratec Se